期刊文献+

特发性肺泡蛋白沉积症患者血清生物标志物的临床意义 被引量:9

Serum markers in patients with idiopathic pulmonary alveolar proteinosis
原文传递
导出
摘要 目的 定量检测血清抗粒细胞巨噬细胞集落刺激因子(GM-CSF)抗体水平,探讨特发性肺泡蛋白沉积症(IPAP)血清生物标志物在其诊断及监测中的意义.方法 连续收集2006年3月至2013年3月北京协和医院就诊的31例IPAP患者,其中男27例,女4例,平均年龄(47±8)岁.纳入同期25名健康体检者及15例胸部CT表现与肺泡蛋白沉积症(PAP)易混淆的住院患者作为疾病对照,所有患者收集血清标本,以ELISA方法分别测定其血清抗GM-CSF抗体、肺泡表面活性物质-A(SP-A)、肺泡表面活性物质-D(SP-D)和软骨糖蛋白-39 (YKL-40)水平,分析其与LDH、癌胚抗原、肺功能和血气等指标的关系.结果 IPAP组患者血清抗GM-CSF抗体、SP-A、SP-D水平分别为29.80(13.02 ~53.86) mg/L、(47±30)和(77±57) μg/L,较健康对照组及疾病对照组升高(P<0.05).YKL-40和LDH水平分别为70.46(48.56 ~90.13) μg/L与(243±56) U/L,与疾病对照组比较差异无统计学意义(P>0.05),较健康对照组升高(P<0.05).癌胚抗原水平为(8 ±6) μg/L,较疾病对照组高(P<0.05).取2.46 mg/L为截断值,血清抗GM-CSF抗体对IPAP诊断的敏感度和特异度均达100%.IPAP组血清LDH、癌胚抗原、SP-A水平分别与P(A-a)O2呈正相关,与TLCO%、PaO2、SaO2呈负相关(P<0.05),SP-D水平与SaO2负相关(P<0.05).SP-A、SP-D水平分别与LDH、癌胚抗原正相关(P<0.05),LDH与癌胚抗原正相关(P<0.05).YKL-40水平与SP-A水平正相关(P<0.05),与其他血清学指标及肺功能、血气指标无线性相关关系(P>0.05).抗GM-CSF抗体与上述指标均无线性相关关系(P>0.05).结论 IPAP患者血清LDH、癌胚抗原、SP-A与SP-D水平均升高,且与疾病严重程度相关;YKL-40水平亦升高,但与疾病严重程度无关;抗GM-CSF抗体与疾病严重度无关.多数IPAP为自身免疫性,通过应用血清抗GM-CSF抗体定量检测方法,验证了其对IPAP诊断有较高的敏感度和特异度,可以用于自身免疫性PAP的诊断. Objective Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by PAS positive lipoproteinaceous material accumulation in the pulmonary alveoli,of which autoimmune (APAP) or idiopathic type (IPAP) accounts for about 90%.Several serum markers were reported to be valuable in IPAP diagnosis.However,data in Chinese patients was not available.Here we analyzed the diagnostic value of serum markers in Chinese IPAP patients.Methods Thirty-one IPAP patients,25 healthy volunteers and 15 patients with other lung diseases were enrolled in the study.Anti-GM-CSF antibody,SP-A,SP-D and YKL-40 levels of the serum samples were tested by ELISA method.LDH,CEA,arterial blood gas analysis and pulmonary function test results were collected and analyzed.Then the difference between the groups and the relationship between the 2 of the markers were tested.Results The level of serum anti-GM-CSF antibody,SP-A and SP-D [29.80(13.02-53.86) mg/L,(47 ± 30) and (77 ± 57) μg/L respectively] were higher in IPAP patients than in healthy volunteers and disease control patients (P < 0.05).IPAP and disease control groups had higher YKL-40 and LDH levels than the healthy control group(P < 0.05),but no statistical difference between the former 2 groups (P > 0.05).The CEA level of IPAP patients was higher than that of the disease control group (P < 0.05).The sensitivity and specificity of anti-GM-CSF antibody in IPAP diagnosis were both 100% at the cut-off value of 2.46 μg/mL.The LDH,CEA and SP-A levels correlated positively with P(A-a) O2 and negatively with TLco%,PaO2 and SaO2 (P < 0.05).The SP-D level correlated negatively with SaO2 (P < 0.05),and positively with LDH and CEA level (P < 0.05),so did SP-A (P < 0.05).YKL-40 correlated positively with SP-A but not with other markers.Anti-GM-CSF antibody did not correlate with any of the markers.Conclusions Serum anti-GMCSF antibody testing showed high sensitivity and specificity for the diagnosis of APAP,though it did not correlate with disease severity.Serum LDH,CEA,SP-A and SP-D levels were elevated in IPAP patients and correlated well with disease severity.YKL-40 level was also higher in IPAP patients,but it could not be used as a disease severity marker.
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2014年第7期497-501,共5页 Chinese Journal of Tuberculosis and Respiratory Diseases
关键词 肺泡蛋白沉积症 抗粒细胞巨噬细胞集落刺激因子抗体 血清生物标志物 Pulmonary alveolar proteinosis Anti-GM-CSF antibody Serum markers
  • 相关文献

参考文献19

  • 1Borie R,Danel C,DebrayMP,et al.Pulmonary alveolar proteinosis[J].Eur Respir Rev,2011,20:98-107.
  • 2Michaud G,Reddy C,Ernst A.Whole-Lung Lavage for Pulmonary Alveolar Proteinosis[J].Chest,2009,136:1678-1681.
  • 3Tanaka N,Watanabe J,Kitamura T,et al.Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor[J].Febs Letters,1999,442:246-250.
  • 4CampoI,Kadija Z,Mariani F,et al.Pulmonary alveolar proteinosis:diagnostic and therapeutic challenges[J].Multidiscip Respir Med,2012,7:4.
  • 5Kitamura T,Uchida K,Tanaka N,et al.Serological diagnosis of idiopathic pulmonary alveolar proteinosis[J].Am J Respir Crit Care Med,2000,162:658-662.
  • 6Bonfield TL,Russell D,Burgess S,et al.Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis[J].Am J Respir Cell Mol Biol,2002,27:481-486.
  • 7徐凯峰,陈燕,郭子健,朱元珏.肺泡蛋白沉积症患者血清中抗粒-巨噬细胞集落刺激因子抗体等血清学指标的临床意义[J].中华结核和呼吸杂志,2004,27(12):824-828. 被引量:34
  • 8Uchida K,Nakata K,Carey B,et al.Standardized serum GMCSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis[J].J Immunol Methods,2014,402:57-70.
  • 9Carey B,Trapnell BC.The molecular basis of pulmonary alveolar proteinosis[J].Clin Immunol,2010,135:223-235.
  • 10李玉茜,陈愉生,李鸿茹,尚颖,高占成.血清粒细胞-巨噬细胞集落刺激因子抗体测定对肺泡蛋白沉积症的诊断价值[J].中华结核和呼吸杂志,2013,36(5):351-356. 被引量:5

二级参考文献21

  • 1徐凯峰,陈燕,郭子健,朱元珏.肺泡蛋白沉积症患者血清中抗粒-巨噬细胞集落刺激因子抗体等血清学指标的临床意义[J].中华结核和呼吸杂志,2004,27(12):824-828. 被引量:34
  • 2Seymour JF,Presneill JJ. Pulmonary alveolar proteinosis:progress in the first 44 years. Am J Respir Crit Care Med,2002,166:215-235.
  • 3Trapnell BC,Whitsett JA,Nakata K. Pulmonary alveolar proteinosis. N Engl J Med,2003,349:2527-2539.
  • 4Kitamura T,Uchida K,Tanaka N,et al. Serological diagnosis of idopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med,2000,162(2 Pt 1):658-662.
  • 5Bonfield TL,Russell D,Burgess S,et al. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol,2002,27:481-486.
  • 6Carraway MS,Ghio AJ,Carter JD,et al. Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med,2000,161(4 Pt 1):1294-1299.
  • 7Bonfield TL,Russell D,Burgess S,et al. Hematopoietic colony stimulating factor in pulmonary alveolar proteinosis(PAP). 98th International Conference of American Thoracic Society,2002 [A35] [poster:C68]. Available from:URL:http://www.thoracic.org/ic/ic2002
  • 8Kavuru MS,Sullivan EJ,Piccin R,et al. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med,2000,161(4 Pt 1):1143-1148.
  • 9Seymour JF,Presneill JJ,Schoch OD,et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med,2001,163:524-531.
  • 10Tanaka N,Watanabe J,Kitamura T,et al. Lungs of patients with idopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett,1999,442:246-250.

共引文献36

同被引文献53

  • 1蔡后荣,崔苏阳,金陵,黄贻真,曹彬,王喆妍,母国华,周贤梅.体外循环膜氧合支持下全肺灌洗治疗肺泡蛋白沉积症一例并文献复习[J].中华结核和呼吸杂志,2005,28(4):242-244. 被引量:20
  • 2王继旺,殷凯生.肺泡蛋白沉积症的研究进展[J].中华结核和呼吸杂志,2007,30(5):375-378. 被引量:12
  • 3Ben-Dov I,Segel MJ.Autoimmune pulmonary alveolar proteinosis:clinical course and diagnostic criteria[J]. Autoimmun Rev,2014,13(4-5):513-517.
  • 4Seymour JF,Presneill JJ.Pulmonary alveolar proteinosis:progress in the first 44 years[J].Am J Respir Crit Care Med,2002,166(2):215-235.
  • 5Tazawa R,Trapnell BC,Inoue Y,et al.Inhaled granulocyte/ macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis[J].Am J Respir Crit Care Med,2010,181(12):1345-1354.
  • 6Inoue Y,Trapnell BC,Tazawa R,et al.Characeristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan[J].Am J Respir Crit Care Med,2008,177(7):752-762.
  • 7Schoch OD,Schanz U,Roller M,et al.BAL finding in a patient with pulmonary alveolar proteinosis successfully treated,with GM- CSF[J].Thorax,2002,57(3):277-280.
  • 8Papiris SA,Tsirigotis P,Kolilekas L.Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis:effectiveness,safety,and lowest effective dose[J].Clin Drug Investig,2014,34(8):553-564.
  • 9Seymour JF,Presneill JJ,Schoch 0D,et al.Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis[J].Am J Respir Crit Care Med,2001,163(2):524-531.
  • 10Khan A,Agarwal R,Aggarwal AN.Effectiveness of granulocyte- macrophage colony-stimulating factor therapy in autoimmune pulmonary alveolar proteinosis:a meta-analysis of observational studies[J].Chest,2012,141(5):1273-1283.

引证文献9

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部